Validation and pharmacological characterisation of MK-801-induced locomotor hyperactivity in BALB/C mice as an assay for detection of novel antipsychotics
- 592 Downloads
We evaluated locomotor hyperactivity induced in BALB/C mice by an N-methyl-d-aspartate receptor antagonist MK-801 as an assay for the detection of antipsychotic drugs.
We assessed the effects of antipsychotic drugs to validate the assay (study 1), selective dopamine and serotonin ligands for pharmacological characterisation of the model (study 2) and a number of compounds with efficacy in models of schizophrenia to understand the predictive validity of the model (study 3).
Adult males (n = 9/group) were pretreated with a test compound, habituated to locomotor activity cages before receiving MK-801 (0.32 mg/kg) and activity recorded for a further 75 or 120 min. In study 1, we tested haloperidol, clozapine, olanzapine, risperidone, ziprasidone, aripiprazole, sertindole and quetiapine. In study 2, we tested SCH23390 (D1 antagonist), sulpiride (D2/D3 antagonist), raclopride (D2/D3 antagonist), SB-277011 (D3 antagonist), L-745,870 (D4 antagonist), WAY100635 (5-HT1A antagonist), 8-OH-DPAT (5-HT1A agonist), ketanserin (5-HT2A/5-HT2C antagonist) and SB-242084 (5-HT2C antagonist). In study 3, we tested xanomeline (M1/M4 receptor agonist), LY379268 (mGluR2/3 receptor agonist), diazepam (GABAA modulator) and thioperamide (H3 receptor antagonist).
All antipsychotics suppressed MK-801-induced hyperactivity in a dose-dependent and specific manner. The effects of antipsychotics appear to be mediated via dopamine D1, D2 and 5-HT2 receptors. Xanomeline, LY379268 and diazepam were active in this assay while thioperamide was not.
MK-801-induced hyperactivity in BALB/C mice model of positive symptoms has shown predictive validity with novel compounds acing at M1/M4, mGluR2/3 and GABAA receptors and can be used as a screening assay for detection of novel pharmacotherapies targeting those receptors.
KeywordsGlutamate MK-801 Schizophrenia Locomotor activity Hyperactivity Antipsychotic
- Andiné P, Widermark N, Axelsson R, Nyberg G, Olofsson U, Mårtensson SM (1999) Characterization of MK-801-induced behaviour as a putative rat model of psychosis. J Pharm Exp Ther 290:1393–1408Google Scholar
- Arrang JM, Garbarg M, Lancelot JC, Lecomte JM, Pollard H, Robba M, Schunack W, Schwartz JC (1987) Highly potent and selective ligands for histamine H3-receptors. Nature 327:117-123Google Scholar
- Brabant C, Alleva L, Grisar T, Quertemont E, Lakaye B, Ohtsu H, Lin JS, Jatlow P, Picciotto MR, Tirelli E (2009) Effects of the H(3) receptor inverse agonist thioperamide on cocaine-induced locomotion in mice: role of the histaminergic system and potential pharmacokinetic interactions. Psychopharmacology 202:673–687CrossRefPubMedGoogle Scholar
- Brady AE, Jones CK, Bridges TM, Kennedy JP, Thompson AD, Heiman JU, Breininger ML, Gentry PR, Yin H, Jadhav SB, Shirey JK, Conn PJ, Lindsley CW (2008) Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats. J Pharmacol Exp Ther 327:941–953CrossRefPubMedGoogle Scholar
- Cartmell J, Monn JA, Schoepp DD (2000) The mGlu2/3 receptor agonists LY379268 selectively blocks amphetamine ambulations and rearing. Eur J Pharmacol 361:39–46Google Scholar
- Conn PJ, Lindsley CW, Jones CK (2008) Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Cell 30:25–31Google Scholar
- Galici R, Echemendia NG, Rodriguez AL, Conn JP (2005) A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteir mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity. J Pharmacol Exp Ther 315:1181–1187CrossRefPubMedGoogle Scholar
- Iverson SD, Singh L, Oles RJ, Preston C, Tricklebank MD (1988) Psychopharmacological profile of the N-methyl-D-aspartate (NMDA) receptor antagonist, MK-801. In: Domino EF, Kamenka JM (eds) Sigma and phencyclidine-like compounds as molecular probes in biology. NPP Books, Ann Arbor, pp 373–384Google Scholar
- Jones CK, Brady AE, Davis AA, Xiang Z, Bubser M, Tantawy MN, Kane AS, Bridges TM, Kennedy JP, Bradley SR, Peterson TE, Ansari MS, Baldwin RM, Kessler RM, Deutch AY, Lah JJ, Levey AI, Lindsley CW, Conn PJ (2008a) Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats. J Neurosci 28:10422–10433CrossRefPubMedGoogle Scholar
- Jones DNC, Gartlon JE, Minassian A, Perry W, Geyer MA (2008b) Developing new drugs for schizophrenia: from animals to the clinic. In: McArthur RA, Borsini F (eds) Animal and translational models for CNS drug discovery, vol 1: psychiatric disorders. Academic, BurlingtonGoogle Scholar
- Keok W, Woods JH, Winger GD (1988) MK-801, a proposed noncompetitive antagonist of excitatory amino acid neurotransmission, produces phencyclidine-like behavioural effects in pigeons, rats and rhesus monkeys. J Pharmacol Exp Ther 245:969–974Google Scholar
- Kinon B (2009) LY2140023 monohydrate and agonist at the mGlu2/3 receptor for the treatment of schizophrenia. A paper presented at the International Congress on Schizophrenia Research in San Diego.Google Scholar
- Maurel-Remy S, Bervoets K, Millan MJ (1995) Blockade of phencyclidine-induced hyperlocomotion by clozapine and MDL 100,907 in rats reflects antagonism of 5-HT2A receptors. Eur J Pharmacol 280:R9-11Google Scholar
- Morisset S, Pilon C, Tardivel-Lacombe J, Weinstein D, Rostene W, Betancur C, Sokoloff P, Schwartz JC, Arrang JM (2002) Acute and chronic effects of methamphetamine on tele-methylhistamine levels in mouse brain: selective involvement of the D(2) and not D(3) receptor. J Pharmacol Exp Ther 300:621–628CrossRefPubMedGoogle Scholar
- Patil S, Zhang L, Martenyi F, Lowe S, Jackson KA, Andreev BV, Avedisova AS, Bardenstein LM, Gurovich IY, Morozova MA, Mosolov SN, Nesnanov NG, Reznik AM, Smulevich AB, Tochilov VA, Johnson BG, Monn JA, Schoepp DD (2007) Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 trial. Nat Med 13:1102–1107CrossRefPubMedGoogle Scholar
- Perera P-Y, Lichy JH, Mastropaolo J, Rosse RB, Deutsch SI (2008) Expression of NR1, NR2A and NR2B NMDA receptor subunits is not altered in the genetically-inbred Balb/c mouse strain with heightened behavioural sensitivity to MK-801, a noncompetitive NMDA antagonist. Eur Neuropsychopharmacol 18:814–819CrossRefPubMedGoogle Scholar
- Prell GD, Green JP, Kaufmann CA, Khandelwal JK, Morrishow AM, Kirch DG, Linnoila M, Wyatt RJ (1995) Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms. Schizophr Res 14:93–104CrossRefPubMedGoogle Scholar
- Reavill C, Taylor SG, Wood MD, Ashmeade T, Austin NE, Avenell KY, Boyfield I, Branch CL, Cilia J, Coldwell MC, Hadley MS, Hunter AJ, Jeffrey P, Jewitt F, Johnson CN, Jones DNC, Medhurst AD, Middlemiss DN, Nash DJ, Riley GJ, Routledge C, Stemp G, Thewlis KM, Trail B, Vong AKK, Hagan JJ (2000) Pharmacological actions of a novel high-affinity, and selective human dopamine D3 receptor antagonist, SB-2777011-A. J Pharmacol Exp Ther 294:1154–1165PubMedGoogle Scholar
- Shannon HE, Rasmussen K, Bymaster FP, Hart JC, Peters SC, Swedberg MD, Jeppesen J, Sheardown MJ, Sauerberg P, Fink-Jensen A (2000) Xanomeline, an M(1)/M(4) prefering muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice. Schizophr Res 42:249–259CrossRefPubMedGoogle Scholar
- Stanhope KJ, Mirza NR, Bickerdike MJ, Bright JL, Harrington NR, Hesselink MB, Kennett GA, Lightowler S, Sheardown MJ, Syed R, Upton RL, Wadsworth G, Weiss SM, Wyatt A (2001) The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat. J Pharmacol Exp Ther 299:782–792PubMedGoogle Scholar
- Southam E, Cilia J, Gartlon JE, Woolley ML, Lacroix LP, Jennings CA, Cluderay JE, Reavill C, Rourke C, Wilson DM, Dawson LA, Medhurst AD, Jones DNC (2009) Preclinical investigation into the antipsychotic potential of the novel histamine H3 receptor antagonist GSK207040. Psychopharmacology 201:483–494CrossRefPubMedGoogle Scholar
- Spooren WPJM, Gasparini F, van der Putten H, Koller M, Nakanishi S, Kuhn R (2000) Lack of effect of LY314582 (a group 2 metabotropic glutamate receptor agonist) on phencyclidine-induced locomotor activity in metabotropic glutamate receptor 2 knockout mice. Eur J Pharmacol 397:R1–R2CrossRefPubMedGoogle Scholar
- Woolley ML, Carter HJ, Gartlon JE, Watson JM, Dawson LA (2009) Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout mice. Eur J Pharmacol 603:147–149CrossRefPubMedGoogle Scholar